Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 753-757

  Stern, Ralph H ^a   Smithers, Jacquelyn A ^a   Olson, Stephen C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P; CYTOCHROME P3A4; FEXOFENADINE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TERFENADINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG CROSS REACTIVITY; DRUG ELIMINATION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN;

EID: 0031865236     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04816.x     Document Type: Article

References (14)

1. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, et al: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-682.
2. Michniewicz BM, Black AE, Sinz MW, Woolf TF: In vitro and in vivo metabolism of atorvastatin (CI-981) (abstract). In, Proceedings of the Sixth North American ISSX Meeting, Raleigh, NC, October 23-27, 1994. Bethesda, MD: International Society for the Study of Xenobiotics, 1994;93.
3. Yun C-H, Okerholm RA, Guengerich FP: Oxidation of the antihistaminic drug terfenadine in human liver microsomes: roles of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-409.
4. Garteiz DA, Hook RH, Walker BJ, Okerholm RA: Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneimittelforschung 1982;32:1185-1190.
5. Lalonde RL, Lessard D, Gaudreault J: Population pharmacokinetics of terfenadine. Pharm Res 1996;13:832-838.
6. Honig PK, Wortham DC, Zamani K, Conner DP, Mulin JC, Cantilena LR: Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269: 1513-1518.
7. Eller MG, Okerholm RA: Pharmacokinetic interaction between terfenadine and ketoconazole (abstract). Clin Pharmacol Ther 1991;49:130.
8. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Cantilena LR: Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-1206.
9. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-238.
10. Honig PK, Wortham DC, Lazarev A, Cantilena LR: Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996;36:345-351.
11. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996;59:383-388.
12. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin Pharmacol Ther 1993;53:630-636.
13. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-1227.
14. Wacher VJ, Wu C-Y, Benet LZ: Overlapping substrate specificities and tissue distribution of Cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogenesis 1995;13:129-134.